Search research articles
Contact Us
Filters
Showing results (131-140 of 194) with videos related to
Page
of 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Cancer Research
|
December 7, 2007
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer
Zhengyan Zhang, Ingrid Borecki, Loan Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 13, 2022
Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variants
Rohit Prakash, Yashpal Rawal, Meghan R Sullivan, et al.
Cancer Research Communications
|
October 31, 2022
Uterine lavage identifies cancer mutations and increased <i>TP53</i> somatic mutation burden in individuals with ovarian cancer
Talayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Gynecologic Oncology
|
September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Mariam M AlHilli, Marc A Becker, S John Weroha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
JAMA Oncology
|
September 14, 2023
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial
Elizabeth M Swisher, Nadine Rayes, Deborah Bowen, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
JAMA Oncology
|
January 1, 2016
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Page
of 20
Search research articles
Search
Showing results (131-140 of 194) with videos related to
Sort By:
Page
of 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Cancer Research
|
December 7, 2007
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer
Zhengyan Zhang, Ingrid Borecki, Loan Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 13, 2022
Homologous recombination-deficient mutation cluster in tumor suppressor <i>RAD51C</i> identified by comprehensive analysis of cancer variants
Rohit Prakash, Yashpal Rawal, Meghan R Sullivan, et al.
Cancer Research Communications
|
October 31, 2022
Uterine lavage identifies cancer mutations and increased <i>TP53</i> somatic mutation burden in individuals with ovarian cancer
Talayeh S Ghezelayagh, Brendan F Kohrn, Jeanne Fredrickson, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Gynecologic Oncology
|
September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Mariam M AlHilli, Marc A Becker, S John Weroha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
JAMA Oncology
|
September 14, 2023
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial
Elizabeth M Swisher, Nadine Rayes, Deborah Bowen, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
JAMA Oncology
|
January 1, 2016
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M Norquist, Maria I Harrell, Mark F Brady, et al.
Page
of 20